Janssen COVID-19 vaccine
A limited supply of the vaccine is available in Peel.
Peel Region will be receiving a limited supply of the Janssen COVID-19 vaccine from the Ontario Ministry of Health. We’re working with the Ontario government to get the doses based on the number of residents who prefer this vaccine.
Do not make a booking through Ontario’s vaccine booking system as the Janssen COVID-19 vaccine is only available on select days at the following pharmacy. You can contact them directly to schedule an appointment.
About the Janssen vaccine
The Janssen COVID-19 vaccine is only authorized for use in people who are 18 years of age and older. It’s a viral vector vaccine which is a type of vaccine that takes another virus, called an adenovirus that is weakened so it cannot grow and teaches your body how to fight against the COVID-19 virus.
It’s recommended that residents get an mRNA vaccine such as Pfizer-BioNTech or Moderna. A single dose of an mRNA vaccine is still preferred over a single dose of the Janssen vaccine. A second dose of mRNA is recommended for most people as it offers higher protection than Janssen.
Discuss your vaccine choices with a health care provider.
The Janssen COVID vaccine should only be used when an mRNA vaccine is declined and after informed consent.
Who should not receive the Janssen vaccine
Individuals with the following conditions should not receive the Janssen COVID-19 vaccine:
- A history of blood clots with low platelets (i.e., major venous or arterial thrombosis with thrombocytopenia) following any vaccine.
- If you had blood clots with low platelets after a previous viral vector vaccine (AstraZeneca or Janssen), you should not receive the Janssen COVID-19 vaccine. Consult with your health care provider.
- Thrombosis with thrombocytopenia syndrome (TTS) or vaccine induced immune thrombotic thrombocytopenia (VITT) following the AstraZeneca COVID-19 vaccine.
- A history of capillary leak syndrome (CLS).
- A history of cerebral venous sinus thrombosis (CVST) with thrombocytopenia.
- A history of heparin-induced thrombocytopenia (HIT).
- Actively receiving monoclonal antibody therapy OR convalescent plasma therapy for the treatment or prevention of COVID-19.
- Vaccine should not be administered while actively receiving therapy.
- Individuals with severe allergic reaction (including anaphylaxis) to a component or ingredient of the Janssen vaccine should discuss their vaccine choices with a health care provider before receiving the Janssen COVID-19 vaccine.
- Individuals who have experienced serious adverse event following COVID-19 immunization should discuss their vaccine choices with a health care provider before receiving the Janssen COVID-19 vaccine.
How much protection the Janssen vaccine provides
Clinical trials show that the Janssen COVID-19 vaccine lowered the chance of getting sick from COVID-19 by 67% and of getting seriously ill by 77%. This protection is somewhat lower than with an mRNA COVID-19 vaccine (Pfizer-BioNTech, Moderna). Because of lower protection and some safety concerns, mRNA vaccines are recommended by the National Advisory Committee on Immunization (NACI).
Ontario recommends that a booster dose of an mRNA COVID-19 vaccine should be given at least 6 months after the Janssen vaccine.
If you have an allergy to an mRNA vaccine, speak with your treating provider about appropriate next steps for a booster dose.